A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents

We propose a hierarchical model for the probability of dose-limiting toxicity (DLT) for combinations of doses of two therapeutic agents. We apply this model to an adaptive Bayesian trial algorithm whose goal is to identify combinations with DLT rates close to a prespecified target rate. We describe methods for generating prior distributions for the parameters in our model from a basic set of information elicited from clinical investigators. We survey the performance of our algorithm in a series of simulations of a hypothetical trial that examines combinations of four doses of two agents. We also compare the performance of our approach to two existing methods and assess the sensitivity of our approach to the chosen prior distribution.

[1]  C. Rudin,et al.  Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  John O'Quigley,et al.  Continual Reassessment Method for Ordered Groups , 2003, Biometrics.

[3]  Peter F Thall,et al.  Simultaneously optimizing dose and schedule of a new cytotoxic agent , 2007, Clinical trials.

[4]  Anastasia Ivanova,et al.  Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.

[5]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[6]  A. Boddy,et al.  Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations , 2005, British Journal of Cancer.

[7]  Peter F Thall,et al.  Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.

[8]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[9]  A Kramar,et al.  Continual reassessment methods in phase I trials of the combination of two drugs in oncology. , 1999, Statistics in medicine.

[10]  Shyamal D Peddada,et al.  Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.

[11]  R L Plackett,et al.  A comparison of two approaches to the construction of models for quantal responses to mixtures of drugs. , 1967, Biometrics.

[12]  Christian P. Robert,et al.  Monte Carlo Statistical Methods , 2005, Springer Texts in Statistics.

[13]  Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer , 2006, British Journal of Cancer.

[14]  W J Shih,et al.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.

[15]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[16]  A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies , 2005, British Journal of Cancer.

[17]  R. Amato,et al.  Phase I/II study of thalidomide in combination with interleukin‐2 in patients with metastatic renal cell carcinoma , 2006, Cancer.

[18]  C. Ahn,et al.  An evaluation of phase I cancer clinical trial designs , 1998 .

[19]  Ying Yuan,et al.  Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.